Optimizing drug release for treating brain cancer
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
This study is looking at a new way to help people with glioblastoma by using special materials that slowly release chemotherapy directly into the brain after surgery, aiming to make treatment more effective and improve survival.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10890780 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for glioblastoma, a highly aggressive brain tumor. It aims to enhance the delivery of chemotherapy directly to the brain by using biodegradable polymers that release drugs over time, thereby overcoming the challenges posed by the blood-brain barrier. By implanting these polymers in the area left after tumor removal, the study seeks to provide a more effective and targeted therapy that could improve patient outcomes. The approach builds on existing treatments like Gliadel®, which has shown some success in extending survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing surgical resection of their tumors.
Not a fit: Patients with other types of brain tumors or those who are not candidates for surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and quality of life for patients with glioblastoma.
How similar studies have performed: Previous research has shown that similar approaches using biodegradable polymers can enhance drug delivery to the brain, indicating potential for success in this area.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Ainslie, Kristy M — Univ of North Carolina Chapel Hill
- Study coordinator: Ainslie, Kristy M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.